Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
According to Jinse Finance APP, shares of Japanese precision motor and industrial equipment manufacturer Nidec fell 9.3%, approaching the 11-month low set earlier this month. This follows UBS downgrading the stock rating from “Buy” to “Neutral” and lowering the target price from 2,800 yen to 2,400 yen, citing a more challenging market environment. UBS also cut its operating profit forecasts for the company for this fiscal year and the next, which are 16% and 22% lower than market consensus respectively.
UBS analysts Shingo Hirata and Kohei Takahashi stated in a report on October 8 that this downgrade reflects a more cautious view of the pace of recovery, due to factors such as overcapacity in the home appliance sector, intensifying competition, and the heavy burden of fixed costs in the industrial motor segment.
They also noted that although Nidec has continuously emphasized its efforts to improve corporate governance, massive impairment charges, management changes, and three consecutive audit reports with disclaimers mean that it may take time for the company to regain the confidence of the capital markets.
Since announcing a significant impairment charge at the end of September, Nidec’s share price has continued to plunge. The impairment has nearly wiped out all profits earned by the company over the past decade.
UBS analysts said that key issues to monitor include whether Nidec can secure an audit opinion by the end of October, submit its internal control report, file its half-year report in November, and publish its mid-term business plan in December.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
BUZZ - After an upgrade by Citi, Australia's QBE Insurance may see its best week in four months
On October 9, shares of Australian QBE Insurance Group (QBE.AX) continued their upward trend, rising 1.8% to AUD 24.805, reaching the highest level since August 5. The stock has gained approximately 4.2% this week and is on track for its best weekly performance since early June. Earlier this week, Citi noted in a report that the insurer stands out from its domestic peers due to its ability to achieve at least mid-single-digit, volume-driven gross written premium (GWP) growth while maintaining underwriting margins. The broker upgraded the stock's rating to "Buy" and raised its target price by 10.3% to AUD 26.70. The report also stated that QBE has currently reached a total premium income of USD 1.5 billions and is expected to increase to USD 2.5 billions in the medium term. Citi added that it remains optimistic about the stock thanks to enhanced earnings stability brought by prudent reserving. So far this year, QBE shares have risen about 25%.
Crypto prices
More
